(Sharecast News) - Coiled Therapeutics said on Tuesday that it had developed a next-generation lipid-based softgel formulation of AO-252, its first-in-class brain-penetrant TACC3 inhibitor, with first patient dosing expected in July 2026.
The AIM-traded company said the new formulation was designed to improve consistency and drug exposure at higher dose levels,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE